Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

被引:159
作者
Schneider, J
Gilbert, SC
Hannan, CM
Dégano, P
Prieur, E
Sheu, EG
Plebanski, M
Hill, AVS
机构
[1] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Mol Immunol Grp,Inst Mol Med, Oxford OX3 9DU, England
[2] Austin Res Inst, Heidelberg, Vic, Australia
关键词
D O I
10.1111/j.1600-065X.1999.tb01326.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
One of the current challenges in vaccine design is the development of antigen delivery systems or vaccination strategies that induce high protective levels of CD8(+) T cells. These cells are crucial for protection against certain rumours and intracellular pathogens such as the liver-stage parasite of malaria. A liver-stage malaria vaccine should therefore include CD8(+) T-cell-inducing components. This review provides an overview of prime-boost immunisation strategies that result in protective CD8(+) T-cell responses against malaria with an emphasis on work from our laboratory. Possible mechanisms explaining why heterologous prime-boost strategies, in particular boosting with replication-impaired recombinant poxviruses, are so effective are discussed.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 67 条
[1]   Comparison of numerous delivery systems for the induction of cytoxic T lymphocytes by immunization [J].
Allsopp, CEM ;
Plebanski, M ;
Gilbert, S ;
Sinden, RE ;
Harris, S ;
Frankel, G ;
Dougan, G ;
Hioe, C ;
Nixon, D ;
Paoletti, E ;
Layton, G ;
Hill, AVS .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) :1951-1959
[2]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[3]   The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses [J].
Antoine, G ;
Scheiflinger, F ;
Dorner, F ;
Falkner, FG .
VIROLOGY, 1998, 244 (02) :365-396
[4]   Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].
Blanchard, TJ ;
Alcamí, A ;
Andrea, P ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167
[5]  
BRUNNER KT, 1968, IMMUNOLOGY, V14, P181
[6]   Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen [J].
Carroll, MW ;
Overwijk, WW ;
Surman, DR ;
Tsung, K ;
Moss, B ;
Restifo, NP .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (24) :1881-1887
[7]   Origin, maturation and antigen presenting function of dendritic cells [J].
Cella, M ;
Sallusto, F ;
Lanzavecchia, A .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (01) :10-16
[8]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[9]  
DEGANO P, IN PRESS VACCINE
[10]   INVIVO PRIMING OF VIRUS-SPECIFIC CYTO-TOXIC LYMPHOCYTES-T WITH SYNTHETIC LIPOPEPTIDE VACCINE [J].
DERES, K ;
SCHILD, H ;
WIESMULLER, KH ;
JUNG, G ;
RAMMENSEE, HG .
NATURE, 1989, 342 (6249) :561-564